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Abstract
The biomanufacturing industry is growing rapidly and becoming one of the key
drivers of personalized medicine and life science. However, biopharmaceutical pro-
duction faces critical challenges, including complexity, high variability, long lead time
and rapid changes in technologies, processes, and regulatory environment. Driven
by these challenges, we explore the bio-technology domain knowledge and propose
a rigorous risk and sensitivity analysis framework for biomanufacturing innovation.
Built on the causal relationships of raw material quality attributes, production process,
and bio-drug properties in safety and efficacy, we develop a Bayesian Network (BN)
to model the complex probabilistic interdependence between process parameters and
quality attributes of raw materials/in-process materials/drug substance. It integrates
various sources of data and leads to an interpretable probabilistic knowledge graph of
the end-to-end production process. Then, we introduce a systematic risk analysis to
assess the criticality of process parameters and quality attributes. The complex produc-
tion processes often involve many process parameters and quality attributes impacting
on the product quality variability. However, the real-world (batch) data are often lim-
ited, especially for customized and personalized bio-drugs. We propose uncertainty
quantification and sensitivity analysis to analyze the impact of model risk. Given very
limited process data, the empirical results show that we can provide reliable and inter-
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pretable risk and sensitivity analysis. Thus, the proposed framework can provide the
science- and risk-based guidance on the process monitoring, data collection, and pro-
cess parameters specifications to facilitate the production process learning and stability
control.
Keywords: Decision analysis, biomanufacturing, Bayesian network, production
process risk analysis, sensitivity analysis
2017 MSC: 00-01, 99-00
1. Introduction
In the past decades, pharmaceutical companies have invested billions of dollars in
the research and development (R&D) of new bio-medicines for the treatment of many
severe illnesses, including cancer cells and adult blindness. More than 40 percent of
the overall pharmaceutical industry R&D and products in the development pipeline are
biopharmaceuticals and this percentage is expected to continuously increase.
Compared to the classical pharmaceutical manufacturing, biopharmaceutical pro-
duction faces several challenges, including complexity, high variability, long lead time
and rapid changes in technologies, processes, and regulatory environment (Kaminsky
& Wang, 2015). Biotechnology products are produced in living organisms, which in-
duces a lot of uncertainty in the production process. Compared to small molecule
drugs, biopharmaceuticals are considerably larger and it is challenging to get the com-
plete evaluation of large-molecule protein drugs. Thus, the (production) process is the
product. The interactions of hundreds of factors impact drug critical quality attributes.
Besides, since the biologic life cycle is short and production lead time is long, there are
limited amounts of historical batch data, in particular for drugs in early development
stages. Therefore, the development of stable, flexible and efficient biomanufacturing
requires us to fully utilize the data, provide a better understanding of production pro-
cess, correctly assess the criticality of process parameters and in-process/final product
quality attributes, and control their specifications.
Kaminsky & Wang (2015) provide the review of Operations research (OR) method-
ologies proposed for biomanufacturing. State-of-the-art studies in the field have several
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key limitations. First, as far as we know, the existing OR approaches introduced for
biomanufacturing still focus on developing general methodologies, and they do not
fully explore the pharmaceutical biotechnology domain knowledge (e.g., the underly-
ing physical mechanics causing the interdependence of raw material quality, production
process, and bio-drug properties in safety and efficacy). For complex biopharmaceu-
tical production process which often has tight batch data, this limits OR methodology
performance and interpretability, as well as its adoption in real applications. Second,
the existing approaches tend to focus on a certain (limited) part of the biomanufactur-
ing system and there is no appropriate and reliable end-to-end risk analysis and control
framework. Some recent works, e.g., Martagan et al. (2016, 2017, 2018), incorporate
physical-chemical characteristics and develop Markov decision models to find the op-
timal operational policies with the scope limited in fermentation and chromatography.
For complex systems, Bayesian network (BN) can be used to combine expert knowl-
edge and data. It can facilitate the end-to-end data integration and analysis in various
applications, including additive manufacturing (Wang et al., 2018), gene co-expression
(Troyanskaya et al., 2003), information system security (Feng et al., 2014) and etc.
Besides, global probabilistic sensitivity analysis can evaluate the contribution of each
random input to the variation of output; see the review in Borgonovo & Plischke (2016).
Since the commonly used variance-based sensitivity measures (i.e., first-order effects
and total effects) fail to adequately account for probabilistic dependence and structural
interactions, Owen (2014) and Song et al. (2016) introduce and study a new sensitivity
measure, called Shapley value (SV), which is motivated by game theory.
Driven by the critical challenges in biomanufacturing, in this paper, we propose a
new BN based risk and sensitivity analysis framework for end-to-end production pro-
cess risk management. It can overcome the key limitations of existing OR methodolo-
gies. By exploring the causal relationships of raw material quality, production process,
and bio-drug properties in safety and efficacy, we first introduce a relational graph that
can meaningfully integrate all the data collected from the production processes. Then,
we develop a BN modeling the underlying probabilistic interdependence of critical
process parameters (CPPs) and critical quality attributes (CQAs) of raw materials/in-
process materials/Active Pharmaceutical Ingredients (API). After that, we propose a
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production process risk analysis to study the contribution of each CPP/CQA to the
output variance and assess their criticality. Since the BN is estimated from limited
real-world batch data, there exists the model risk (MR). We further introduce uncer-
tainty quantification (UQ) and sensitivity analysis (SA) to study the impact of MR
on the production process risk analysis. Thus, the proposed framework can facilitate
the systematic learning and guide the science- and risk-based process monitoring and
CPPs/CQAs specification to improve the production process stability.
This paper is organized as follows. In Section 2, we present the problem descrip-
tion. Then, we propose a production process risk analysis in Section 3, and further
introduce BN based uncertainty quantification and sensitivity analysis in Section 4.
We conduct the empirical study in Section 5 and conclude this paper in Section 6.
2. Problem Description and Proposed Framework
We propose a systematic BN-SV-MR based risk and sensitivity analysis framework
to facilitate the understanding and stability control for end-to-end biopharmaceutical
production processes. Since biopharmaceuticals are produced in living organisms, the
production process involves up to hundreds of factors determining the product quality;
see a simplified illustration in Figure 1. The production process includes the main unit
operations: (1) media preparation, (2) inoculum fermentation, (3) main fermentation,
(4) centrifugation(s), (5) chromatography/purification, (6) filtration, (7) fill and finish,
and (8) quality control. Steps (1)–(3) belong to upstream cell culture, Steps (4)–(6)
belong to downstream target protein purification, and Steps (7)–(8) are for finished
drug filling/formulation and final product quality control testing.
The interactions of many factors impact the variability of drug quality; see the
fishbone representation of the production process in Figure 1. In general, these factors
can be divided into CPPs and CQAs; see the definitions of CPPs/CQAs in ICH Q8(R2).
CPP: At each process unit operation, CPPs are defined as those parameters whose
variability has an impact on critical quality and therefore should be monitored
and controlled to ensure the process produces the desired quality.
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Figure 1: A general biomanufacturing process (Walsh, 2013).
CQA: A physical, chemical, biological, or microbiological property or characteristic
that should be within an appropriate limit, range, or distribution to ensure the
desired product quality.
Since the raw material attributes are outputs of release materials, they should be con-
sidered along with CPPs as impacting process variability.
We represent the variability of any bio-drug critical quality attribute with a random
variable (r.v.), denoted by Y . It depends on the random inputs, denoted by X, including
selected CPPs/CQAs and other variables introduced in the production process opera-
tions (e.g., contamination), denoted by e. Thus, we model the complex interactions
of inputs (X,e) and production process impacting on the response by Y = g(X,e|θ ),
where g(·) is a unknown function specified by parameters θ . The proposed framework
can be naturally extended to a vector of responses.
There are two types of uncertainty: stochastic uncertainty (inherent variability of
biopharmaceutical production process, i.e., random inputs X and e) and model risk (i.e.,
limited knowledge on statistical models for (X,e) and function g(·|θ ) representing the
complex interactions). We can control the impact of stochastic uncertainty by improv-
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ing the production process CPPs/CQAs specifications/control and reduce the model
risk through process monitoring and data collection.
To produce a successful batch, there could exist more than 100 factors that need
to be considered (Otto et al., 2014). We explore the causal relationships of underlying
physical mechanics causing the interdependence of raw material quality, production
process, and bio-drug properties in safety and efficacy. We further develop a BN with
parameters θ modeling the complex probabilistic interdependence, Y = g(X,e|θ ). We
measure the variability of product quality by the output variance, Var(Y ). The contribu-
tion of any random input from X and e to Var(Y ) can be quantified by variance-based
sensitivity measures. In Section 2.1, we review relevant sensitivity measures, espe-
cially focusing on the SV utilized in this paper. Then, before providing the detailed
presentation in Sections 3 and 4, we summarize and provide the insights of the pro-
posed production process risk and sensitivity analysis framework accounting for both
stochastic uncertainty and model risk in Section 2.2.
2.1. Variance-based Sensitivity Measures - Shapley Value
Since hundreds of factors could impact on the product critical attributes, we want
to identify those inputs that can reduce the output variance Var(Y ) the most. The con-
tribution of each input, Wk in W = (X,e) with k ∈K , to the output variance relies on
probabilistic dependence and structural interactions, where K represents the index
set of all inputs in W. Here, the probabilistic dependence represents the underlying in-
terdependence among different inputs (e.g., the CQAs of raw materials and in-process
products) and the structural interactions are induced by the complex production process
logic. Two most commonly used variance-based sensitivity measures are: (1) the first-
order effect Vk ≡Var(Y )−E[Var(Y |Wk)] that considers the variance reduction when we
fix Wk; and (2) the total effect Tk ≡ E[Var(Y |W−k)] that considers the expected remain-
ing variance when all other inputs, denoted by W−k, are fixed. However, both measures
fail to appropriately quantify the sensitivity when there exist probabilistic dependence
and/or structural interaction among inputs (Song et al., 2016).
In this paper, we consider the SV, a new variance-based sensitivity measure intro-
duced by Owen (2014). It can overcome the limitations of first-order effect and total
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effect measures. SV was originally introduced to evaluate the performance of a player
in a cooperative game from game theory (Shapley, 1953). In the proposed framework,
it is used to quantify the contribution of each random input Wk to the output variance
Var(Y ), defined as
Sh(Wk) = ∑
J⊂K /{k}
(K−|J |−1)!|J |!
K!
[c(J ∪{k})− c(J )] , (1)
where K = |W| denotes the total number of random inputs and |J | is the size of index
subsetJ fromK /{k}; see the description and motivation of SV in Owen (2014) and
Song et al. (2016). Since (K−s−1)!s!K! =
1
K
(K−1
s
)−1
, we put equal weight to all possible
sizes of subsets (s = 0,1, . . . ,K− 1) and also equal weight to all possible subsets of
size s. The cost function c(J ) represents the variance of Y induced by random inputs
in any subset WJ . Here, we set the cost function c(J ) to be the expected remaining
variance of response Y when all other input factors W−J = WK \J are fixed,
c(J ) = E[Var[Y |W−J ]].
Then, c(J ∪{k})− c(J ) is the expected increment of Var[Y |W−J ] induced by in-
cluding Wk into the set WJ . Therefore, Sh(Wk) defined in Equation (1) can be in-
terpreted as the average variance Var(Y ) increment induced by including Wk into all
possible subsets WJ , which allows us to appropriately account for probabilistic de-
pendence and structural interaction.
The main benefits of SV over first-order and total effect sensitivity measures in-
clude: (1) the uncertainty contributions sum up to total variance of output; (2) SV can
automatically account for probabilistic dependence and structural interactions occur-
ring in the complex production process; and (3) combing SV with BN (represented
by BN-SV) can facilitate the appropriate and interpretable risk and sensitivity analysis
since BN is built based on underlying physical mechanics causing the interdependence
of raw material quality, production process, and bio-drug properties.
7
2.2. Summary of Proposed Process Risk and Sensitivity Framework
In Section 3, we first explore the causal relationships of CPPs/CQAs of raw
materials/in-process materials/API and develop a BN specified by parameters θ . Since
we often have limited batch data, it can efficiently model the complex probabilistic
interdependence of production process and improve the interpretability. Then, we
derive the variance decomposition, Var(Y |θ ) = ∑Xk Sh(Xk|θ ) +∑ek Sh(ek|θ ), where
the SVs, Sh(Xk|θ ) and Sh(ek|θ ), measure the contribution of any CPP/CQA Xk ∈ X
and other factor ek ∈ e to Var(Y |θ ). Then, the criticality, defined by pWk,Y (θ ) ≡
Sh(Wk|θ )/Var(Y |θ ), can be used to identify those inputs Wk (i.e., Xk or ek) that can
reduce Var(Y ) the most. Thus, the proposed BN-SV based risk analysis can improve
our understanding of the end-to-end production process, and facilitate the CPPs/CQAs
specification and control to efficiently reduce the output variation.
The “correct” BN parameters, denoted by θ c, characterizing the underlying proba-
bilistic interdependence of the production process is unknown. We estimate it by using
the real-world data, denoted by X , collected from the production process, and quan-
tify the model risk (MR) with the posterior distribution p(θ |X ). In Section 4, we first
characterize the estimation uncertainty of variance contribution from any random input
Wk with the posterior distribution of Sh(Wk|θ˜ ) with θ˜ ∼ p(θ |X ). In this paper, we
use ·˜ to denote any posterior sample. We can use the posterior variance to quantify
the overall estimation uncertainty, Var∗[Sh(Wk)|X ] ≡ Var∗p(θ |X )[Sh(Wk|θ˜ )|X ]. The
subscript “∗” represents any measure calculated based on the posterior p(θ |X ).
Since the BN is built on underlying physical mechanics of the production process,
we can find the subset of BN parameters determining Sh(Wk), denoted by θ (Wk,Y ).
We introduce the BN-SV-MR based sensitivity analysis to provide the comprehensive
study over the impact of model risk. We derive the posterior variance decomposition,
Var∗[Sh(Wk)|X ] = ∑θ`∈θ (Wk,Y )Sh∗θ`
[
Sh
(
Wk
∣∣∣θ˜ (Wk,Y ))∣∣∣X ]= ∑θ`∈θ (Wk,Y )Sh∗θ` [Sh(Wk)|X ] , (2)
where Sh∗θ` [ ·|X ] measures the contribution from parameter uncertainty on θ` ∈
θ (Wk,Y ). Since θ` represents a certain part of production process, the decomposi-
tion in (2) provides the detailed information on how the model risk over the end-to-end
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production process influences the estimation uncertainty of Sh(Wk). It can be used to
guide the knowledge improvement through process monitoring and data collection.
In sum, the proposed framework can provide systematic production process risk
analysis and assess the criticality or contribution of each CPP/CQA to the output vari-
ance. It accounts for the impact from model risk. Thus, the framework can provide
reliable guidance on CPPs/CQAs monitoring and specifications, as well as quality
control for raw materials, intermediate and final products, so that we can efficiently
improve the stability of integrated biopharmaceutical production process.
3. Integrated Production Process Risk Analysis
Here we introduce an end-to-end production process risk analysis. In Section 3.1,
we explore the causal relationships and introduce a relational graph to meaningfully
connect all sources of data collected from various process unit operations. Then, in
Section 3.2, we develop a probabilistic knowledge graph or Bayesian network mod-
eling the complex interdependence between raw material quality, production process,
and bio-drug properties in safety and efficacy. In Section 3.3, we propose the BN-SV
risk analysis, assess the criticality of each CPP/CQA or any other factor, and identify
the main sources of uncertainty contributing the most to the product quality variation;
see the algorithm for production process risk analysis in Appendix D.
3.1. Relational Graphical Model for Production Process
Based on the interactions of CPPs/CQAs and other factors in each process unit
operation and also connections among production steps, we develop a relational graph-
ical model for biopharmaceutical production process from raw materials to finished
drug substance; see Figure 2 for illustration. In the graph, nodes represent factors (i.e.,
CPPs and CQAs) impacting on the product quality. The directed edges model the input-
output dependence in each process unit and also the interdependence among different
production steps. Each big dashed box in Figure 2 illustrates one process unit opera-
tion. The shaded nodes represent the variables with real-world observations, including
the testing and sensor monitoring data of CPPs/CQAs for raw materials, intermediate
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and final drug products. The unshaded and dashed nodes represent variables with-
out observations, including the complete quality status of intermediate and final drug
products, and other uncontrollable factors (e.g., contamination) introduced during the
process unit operations. Since protein drugs have very complex structures, we can not
observe the underlying complete quality status and the monitoring of CQAs can carry
partial information.
Pre-
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Figure 2: Relational graph for biopharmaceutical production process.
3.2. Bayesian Network Development for Production Process
Based on the relational graph introduced in Section 3.1, we develop a BN proba-
bilistic graphical model composing of random variables and their conditional depen-
dencies via directed edges. For biopharmaceutical production processes, it can char-
acterize the probabilistic interdependence between CPPs and CQAs of raw materials,
intermediate product/materials, and API.
3.2.1. Bayesian Network Modeling Development Illustrated with An Example
Without loss of generality, we use a simple example including two production steps
(say media preparation and main fermentation) in Figure 3 to illustrate the probabilis-
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tic graphical model development. It is based on the causal relationships and the in-
teractions between CPPs and CQAs. Each node represents a CPP/CQA with a r.v. X
modeling its variability. Each directed edge with parameter βi j represents the impact of
parent node Xi on child node X j. The pattern-fill nodes (X1,X2,X3) represent the CPPs.
The solid fill nodes (X6,X7) represent the monitored CQAs of intermediate materials
and drug products. The nodes X4 and X5 represent the underlying complete quality
status of media and drug product after main fermentation. The CQAs X6 and X7 repre-
sent the partial information of quality variables X4 and X5. Except the CPPs X1,X2,X3,
the impacts from other factors (i.e., uncontrollable factors) introduced during media
preparation and main fermentation are modeled through e′4 and e
′
5.
Figure 3: Left: knowledge relational graph; Right: simplified knowledge graph.
Since X4 and X5 are hidden and also it is hard to uniquely specify the underlying
properties of media and product, they could lead to the identification issue. Thus, we
simplify and transform the relational graphical model to a graph without hidden nodes,
depicted in the right panel of Figure 3. The CQA X6 only carries the partial information
of the underlying media quality X4, and e6 accounts for the impact from factor e′4 on
X6. Combining with other factor e′5, the impact of remaining media properties on the
CQA X7 is modeled through e7.
According to the right plot in Figure 3, the sources of uncertainty impacting on the
variability of X7 include the process parameters X1,X2,X3 and other factors e6,e7. In
each process unit operation, we have CPPs X1,X2 as inputs and CQA X6 as output for
the first step, and have CQA X6 and CPP X3 as inputs and X7 as output for the second
step. To study the impact of each CPP on the CQA of interest (e.g., X6 and X7), we can
decompose the variance of X6 and X7 into the contributions from X1, X2 and X3, and
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remaining parts coming from e6 and e7. In this way, we can identify the main sources of
uncertainty and quantify their impacts, which can guide the CPPs/CQAs specifications
and the quality control to improve the product quality stability.
Since there are often limited batch data, in Section 3.2.2, we develop a Gaussian
Bayesian network modeling the probabilistic interdependence of production process.
Then, we derive a variance decomposition and propose a systematic BN-SV based risk
analysis to estimate the criticality of each CPP/CQA in Section 3.3.
3.2.2. Gaussian Bayesian Network Model Development
We consider a probabilistic graphical model with m+1 nodes representing the in-
terdependence of CPPs/CQAs (X), bio-product critical quality attribute (Y or Xm+1)
and other factors (e). Let the first mp nodes representing CPPs Xp = {X1,X2, . . . ,Xmp},
the next ma nodes representing CQAs Xa = {Xmp+1,Xmp+2, . . . ,Xm}, and the last node
representing the response Y , Xm+1 with m = mp+ma. We construct the linear Gaus-
sian model of the marginal and conditional distributions for each node as follows:
Xk ∼ N (µk,v2k) for CPP Xk with k = 1,2, . . . ,mp, (3)
Xk = µk + ∑
X j∈Pa(Xk)
β jk(X j−µ j)+ ek for CQA Xk with k = mp+1, . . . ,m+1(4)
where Pa(Xk) denotes the parent nodes of Xk, and we assume ek ∼N (0,v2k) with the
conditional variance v2k = Var[Xk|Pa(Xk)].
Given the BN parameters θ = (µ ,v2,β ) with mean µ = (µ1, . . . ,µm+1)>, condi-
tional variance v2 =(v21, . . . ,v
2
m+1)
>, and linear coefficientsβ = {β jk;k=mp+1, . . . ,m+
1 and X j ∈ Pa(Xk)}, the conditional distribution for each CQA node Xk,
p(Xk|Pa(Xk)) =N
µk + ∑
X j∈Pa(Xk)
β jk(X j−µ j),v2k
 for k = mp+1 . . . ,m+1. (5)
For any CPP node Xk without parent nodes, Pa(Xk) is an empty set and P(Xk|Pa(Xk))
is just the marginal distribution P(Xk) in (3). Let Zk
i.i.d.∼ N (0,1) and (5) becomes
Xk = µk+∑X j∈Pa(Xk)β jk(X j−µ j)+vkZk. Thus, the joint distribution characterizing the
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interdependence of CPPs and CQAs involved in the production process can be written,
p(X1,X2, . . . ,Xm+1) =∏m+1k=1 p(Xk|Pa(Xk)).
3.3. CPPs and CQAs Criticality Assessment
Given the BN parameters θ = (µ ,v2,β ), we present the BN-SV based risk analysis
for the end-to-end production process and further quantify the criticality of each ran-
dom input through measuring its contribution to the product quality variance Var(Xm+1).
3.3.1. CPPs Impact on CQAs of Intermediate and Final Products
We derive the SV quantifying the contribution of each random input from CPPs Xp
and other factors e to Var(Xm+1). Suppose Xp and e are independent with each other.
According to the Gaussian BN model presented in (3) and (4), we can derive
Xm+1 = µm+1+
mp
∑
k=1
γk,m+1(Xk−µk)+
m+1
∑
k=mp+1
γk,m+1ek, (6)
where the weight coefficient of any CPP Xk to CQA Xn with k ≤ mp < n≤ m+1,
γkn = βkn+ ∑
mp<`<n
βk`β`n+ ∑
mp<`1<`2<n
βk`1β`1`2β`2n+. . .+βk,mp+1βmp+1,mp+2 . . .βn−1,n,
(7)
the weight coefficient of any ek to a CQA node Xn with mp < k < n≤ m+1,
γkn = βkn+ ∑
k<`<n
βk`β`n+ ∑
k<`1<`2<n
βk`1β`1`2β`2n+ . . .+βk,k+1βk+1,k+2 . . .βn−1,n; (8)
and γnn = 1 for any n; see the derivation for (6) in Appendix A. The weight coefficient
γkn accounts for all paths from node Xk to node Xn in the BN.
Let W = {X1, . . . ,Xmp ,emp+1, . . . ,em+1} , {W1,W2, . . . ,Wm+1} represent all ran-
dom inputs, including the variability from raw materials and production process. De-
note the index setK = {1,2, . . . ,m+1}. Then, the SV for the k-th input factor Wk is,
Sh(Wk) = ∑
J⊂K /{k}
(m−|J |)!|J |!
(m+1)!
[c(J ∪{k})− c(J )] .
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Based on (6), we compute the cost function c(J ) = E[Var[Xm+1|W−J ]] =
∑k∈J γ2k,m+1v
2
k , and obtain c(J ∪{k})− c(J ) = γ2k,m+1v2k . Given the BN parame-
ters θ , we derive Sh(Xk|θ ) for any CPP Xk with k = 1, . . . ,mp,
Sh(Xk|θ ) = ∑J⊂K /{k}
(m−|J |)!|J |!
(m+1)!
γ2k,m+1v
2
k = γ
2
k,m+1v
2
k∑
m
s=0
(m− s)!s!
(m+1)!
(m
s
)
= γ2k,m+1v
2
k ,
and Sh(ek|θ ) = γ2k,m+1v2k for any other factor ek with k = mp + 1, . . . ,m+ 1. There-
fore, we can decompose the variance of drug substance attribute Xm+1 and estimate the
contribution from each random input from Xp and e,
Var(Xm+1|θ ) =
mp
∑
k=1
Sh(Xk|θ )+
m+1
∑
k=mp+1
Sh(ek|θ ) =
mp
∑
k=1
γ2k,m+1v
2
k +
m+1
∑
k=mp+1
γ2k,m+1v
2
k . (9)
Equation (9) can be used to identify the dominant factors in Xp and e contributing the
most to the product quality variance, which can guide the parameters specification to
improve the production process stability. As a result, given the BN parameters θ , the
criticality of any input Wk can be quantified by pWk,Xm+1(θ )≡ Sh(Wk|θ )/Var(Xm+1|θ ).
In addition, we can assess the impact of inputs on any intermediate product CQA,
say Xi with mp < i < m+ 1. Let Xp(Xi) denote a set containing all CPPs from previ-
ous process unit operations impacting on Var(Xi|θ ). For example in Figure 3(b), we
consider the subgraph {X1,X2,X6} and then Xp(X6) = {X1,X2}. Following the similar
derivation as that for (6), we have
Xi = µi+ ∑
Xk∈Xp(Xi)
γki(Xk−µk)+
i
∑
k=mp+1
γkiek. (10)
We can compute the SV measuring the contribution from each factor Xk or ek′ on the
variance of CQA Xi: Shi(Xk|θ ) = γ2kiv2k and Shi(ek′ |θ ) = γ2k′iv2k′ for {k : Xk ∈ Xp(Xi)}
and k′ = mp +1, . . . , i. Thus, we can decompose the variance of CQA Xi to the contri-
bution from each source of uncertainty as
Var(Xi|θ ) = ∑
Xk∈Xp(Xi)
Shi(Xk|θ )+
i
∑
k=mp+1
Shi(ek|θ ) = ∑
Xk∈Xp(Xi)
γ2kiv
2
k +
i
∑
k=mp+1
γ2kiv
2
k .
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3.3.2. CQAs and CPPs Impact on Final Product or Intermediate CQA
Here we consider the partial production process including one or multiple process
unit operations. Suppose that we start from certain operation unit and want to esti-
mate the impact of starting CQAs and remaining steps CPPs on the intermediate or
final product CQA of interest. For example, in Figure 3(b), we consider the subgraph
{X3,X6,X7} with the starting CQA X6 carrying some information from previous oper-
ation step. We study the impacts of X6 and CPP X3 on the variability of CQA X7.
Define the complete BN model with parameters θ as G(N|θ ), where the set N =
{X1, . . . ,Xm+1} includes all nodes. Suppose the part of production process of interest
is represented by a subgraph G(N′|θ (N′)) having the node set denoted by N′ ⊆N with
size n′ = |N′| and the index set denoted byK ′. We define the set including the starting
CQAs as Xa(N′) = {Xk ∈ (Xa∩N′) : Pa(Xk)∩N′= /0}, i.e., any CQA node in N′ having
parent nodes located out of N′. Define the set of CPP nodes as Xp(N′) = {Xp ∩N′}.
Then each remaining CQA node X j ∈ N′/(Xa(N′)∪Xp(N′)) has the corresponding
variation factor e j. Denote the set of e j’s in the subgraph as e(N′). Without loss of
generality, suppose there is a node Xi ∈ N′ (mp < i≤ m+1) without succeeding nodes
in N′.
We quantify the contributions of random inputs for the subgraph, including starting
CQAs and CPPs, to Var(Xi|θ ). Following the idea similar with (6), we obtain that
Xi = µi+ ∑
Xk∈Xp(N′)
γki(Xk−µk)+ ∑
Xk∈Xa(N′)
γki(Xk−µk)+ ∑
ek∈e(N′)
γkiek. (11)
Notice that CQAs in Xa(N′) could be dependent on each other. The Shapley value
used for risk analysis can correctly account for both probabilistic dependence and
structural interaction of input factors. Let W ′ = {Xp(N′)∪Xa(N′)∪ e(N′)} , {Wk :
k ∈K ′} represent all random inputs in the subgraph. For any index subsetJ ⊂K ′,
by applying (11), we get
c(J ) = E[Var[Xi|W ′−J ]] = ∑
k∈J
γ2kiVar(Wk)+2 ∑
k1<k2∈J
γk1iγk2iCov(Wk1 ,Wk2).
Suppose any CPP Xk ∈ Xp(N′) or factor ek ∈ e(N′) is independent with other inputs in
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W ′. It implies Cov(Wk1 ,Wk2) = 0 if either Wk1 ∈ {Xp(N′)∪e(N′)} or Wk2 ∈ {Xp(N′)∪
e(N′)}. When both Wk1 = Xk1 and Wk2 = Xk2 are CQAs belonging to Xa(N′), the
covariance can be computed by using the linear representation in (10),
Cov(Xk1 ,Xk2) = ∑
X`∈{Xp(Xk1 )∩Xp(Xk2 )}
γ`k1γ`k2v
2
` +
min(k1,k2)
∑
`=mp+1
γ`k1γ`k2v
2
` ; (12)
see the derivation in Appendix B. Then, for each Wk andJ ⊂K ′/{k}, we can obtain
c(J ∪{k})− c(J ) = γ2kiVar(Wk)+2 ∑
`∈J
γkiγ`iCov(Wk,W`),
=
γ
2
kiv
2
k , Wk = Xk ∈ Xp(N′) or Wk = ek ∈ e(N′)
γ2kiVar(Xk|θ )+2∑X`∈Xa(N′),`∈J γkiγ`iCov(Xk,X`|θ ), Wk = Xk ∈ Xa(N′)
where Var(Xk|θ ) is the variance of starting CQAs Xk and it can be calculated by apply-
ing (11) or estimated by using the real-world data. Then, the SV of each input Wk on
the drug quality CQA Xi with mp < i≤ m+1 can be calculated as follows:
Shi(Wk|θ ) = ∑
J⊂K /{k}
(n′−|J |−1)!|J |!
n′!
[c(J ∪{k})− c(J )]
= γ2kiVar(Wk)+ ∑`
6= j
γkiγ`iCov(Wk,W`)
=

γ2kiv
2
k , Wk = Xk ∈ Xp(N′) or Wk = ek ∈ e(N′)
γ2kiVar(Xk|θ )+∑X`∈Xa(N′)/{Xk}
(
∑Xh∈{Xp(Xk)∩Xp(X`)} γhkγkiγh`γ`iv
2
h
+∑min(k,`)h=mp+1 γhkγkiγh`γ`iv
2
h
)
, Wk = Xk ∈ Xa(N′).
(13)
The derivation of (13) is provided in Appendix C. Thus, we have the variance decom-
position:
Var(Xi|θ ) = ∑
Xk∈Xp(N′)
Shi(Xk|θ )+ ∑
Xk∈Xa(N′)
Shi(Xk|θ )+ ∑
ek∈e(N′)
Shi(ek|θ )
= ∑
Xk∈Xp(N′)
γ2kiv
2
k + ∑
Xk∈Xa(N′)
[
γ2kiVar(Xk|θ )+ ∑
X`∈Xa(N′)/{Xk}
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(
∑
Xh∈{Xp(Xk)∩Xp(X`)}
γhkγkiγh`γ`iv2h+
min(k,`)
∑
h=mp+1
γhkγkiγh`γ`iv2h
)]
+ ∑
ek∈e(N′)
γ2kiv
2
k . (14)
The criticality of Wk on Xi can be measured by pWk,Xi(θ ) = Shi(Wk|θ )/Var(Xi|θ ).
4. Uncertainty Quantification and Sensitivity Analysis
Since the “correct” BN parameters θ c are unknown, given finite real-world data
X , there exists the model risk (MR) characterizing our limited knowledge on the
underlying probabilistic interdependence of raw material quality, production process,
and bio-drug safety and efficacy. To study the impact of MR on the production pro-
cess risk analysis and CPPs/CQAs criticality assessment, we propose the BN-SV-MR
based UQ and SA which can guide the risk- and science-based process monitoring and
data collection. In Section 4.1, we develop the Bayesian learning, derive the posterior
p(θ |X ) and provide a Gibbs sampler to generate posterior samples, θ˜ (b) ∼ p(θ |X )
with b= 1,2, . . . ,B, quantifying the model risk. Then, in Section 4.2, we present UQ to
quantify the estimation uncertainty of variance contribution and criticality of any ran-
dom input Wk. In Section 4.3, we propose the BN-SV-MR based SA that can provide
the comprehensive study on how the MR over each part of the end-to-end production
process impacts on the risk analysis and the CPPs/CQAs criticality assessment.
4.1. Bayesian Learning for Model Risk Quantification
We first study the case with R batches of complete production process data, denoted
as X = {(x(r)1 ,x(r)2 , . . . ,x(r)m+1),r = 1,2, . . . ,R}. Without strong prior information, we
consider the following non-informative prior,
p(µ ,v2,β ) =
m+1
∏
i=1
p(µi)p(v2i ) ·∏
i 6= j
p(βi j), (15)
with p(µi)=N (µ
(0)
i ,σ
(0)2
i ), p(v
2
i )= Inv-Γ
(
κ(0)i
2
,
λ (0)i
2
)
and p(βi j)=N (θ
(0)
i j ,τ
(0)2
i j ),
where Inv-Γ denotes the inverse-gamma distribution. Given the data X , by applying
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the Bayes’ rule, we can obtain the posterior distribution
p(µ ,v2,β |X ) ∝
R
∏
r=1
[
m+1
∏
i=1
p(x(r)i |x(r)Pa(Xi))
]
p(µ ,v2,β ), (16)
quantifying the estimation uncertainty of the BN model characterizing the probabilistic
interdependence of production process.
To develop a Gibbs sampler for the posterior distribution in (16), we derive the
conditional posterior for each parameter in (µ ,v2,β ). Let µ−i, v2−i and β−i j denote the
collection of parameters µ ,v,β excluding the i-th or (i, j)-th element. Let S(Xi) denote
the set of direct succeeding or child nodes of node Xi. We first derive the conditional
posterior for the coefficient βi j,
p(βi j|X ,µ ,v2,β−i j) =N (θ (R)i j ,τ(R)2i j ), (17)
where θ (R)i j =
τ(0)2i j ∑
R
r=1α
(r)
i m
(r)
i j + v
2
jθ
(0)
i j
τ(0)2i j ∑
R
r=1α
(r)2
i + v
2
j
and τ(R)2i j =
τ(0)2i j v
2
j
τ(0)2i j ∑
R
r=1α
(r)2
i + v
2
j
with
α(r)i = x
(r)
i − µi and m(r)i j = (x(r)j − µ j)−∑Xk∈Pa(X j)/{Xi}βk j(x
(r)
k − µk). Then, we de-
rive the conditional posterior for v2i = Var[Xi|Pa(Xi)] with i = 1,2, . . . ,m+1,
p(v2i |X ,µ ,v2−i,β ) = Inv-Γ
(
κ(R)i
2
,
λ (R)i
2
)
, (18)
where κ(R)i = κ
(0)
i +R, λ
(R)
i = λ
(0)
i +∑
R
r=1 u
(r)2
i and u
(r)
i =(x
(r)
i −µi)−∑Xk∈Pa(Xi)βki(x
(r)
k −
µk). After that, we derive the conditional posterior for the mean parameter µi with
i = 1,2, . . . ,m+1 for any CPP/CQA,
p(µi|X ,µ−i,v2,β ) ∝ p(µi)∏Rr=1
[
p(x(r)i |x(r)Pa(Xi))∏ j∈S (Xi) p(x
(r)
j |x(r)Pa(X j))
]
=N (µ(R)i ,σ
(R)2
i ), (19)
where µ(R)i =σ
(R)2
i
 µ(0)i
σ (0)2i
+∑Rr=1
a(r)i
v2i
+∑Rr=1∑X j∈S(Xi)
βi jc
(r)
i j
v2j
 and 1
σ (R)2i
=
1
σ (0)2i
+
R
v2i
+∑X j∈S(Xi)
Rβ 2i j
v2j
with a(r)i = x
(r)
i −∑Xk∈Pa(Xi)βk j(x
(r)
k −µk) and c(r)i j = βi jx(r)i −(x(r)j −
µ j)+∑Xk∈Pa(X j)/{Xi}βk j(x
(r)
k − µk). The Gibbs sampler iteratively draws the posterior
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samples of (µ ,v2,β ) by applying the conditional posterior distributions given in (17),
(18), and (19) until convergence (Gelman et al. 2004).
Besides the case with complete production data, we often have additional incom-
plete batch data. Since the lead time for biopharmaceutical production is lengthy (Otto
et al., 2014), we can have some batches in the middle of production. In addition, the
bio-drug quality requirements are restricted, especially for human drugs. Following the
quality control, we could discard some batches after main fermentation or even in the
middle of downstream purification. Thus, we provide the description, derivation and
Gibbs sampler (see Algorithm 3) for both cases with complete or mixing data in online
Appendix E.1.2.
4.2. Uncertainty Quantification Accounting for Model Risk
Here we present the UQ to study the overall impact of BN model risk on the produc-
tion process risk analysis and CPPs/CQAs criticality assessment. Based on Section 3.3,
the contribution from any random input Wk in W ≡ {Xp ∪Xa ∪ e} to the variance of
product quality attribute Xm+1 is measured by the Shapley value, Sh(Wk|θ c). The un-
known parameters θ c specifying the underlying probabilistic interdependence of pro-
duction process are estimated by using limited real-world dataX . Thus, the estimation
uncertainty of the contribution from input Wk can be quantified by the posterior distri-
bution, Sh(Wk|θ˜ ) with θ˜ ∼ p(θ |X ). We can use the posterior mean to estimate the
expected variance contribution and criticality, E∗[Sh(Wk)|X ]≡E∗p(θ |X )[Sh(Wk|θ˜ )|X ]
and E∗[pWk,Xm+1 |X ] ≡ E∗p(θ |X )[pWk,Xm+1(θ˜ )|X ], where pWk,Xm+1(θ˜ ) =
Sh(Wk|θ˜ )
Var(Xm+1|θ˜ )
.
The posterior variance is used to quantify the overall estimation uncertainty induced
by MR, Var∗[Sh(Wk)|X ]≡ Var∗p(θ |X )[Sh(Wk|θ˜ )|X ] and Var∗[pWk,Xm+1 |X ]≡
Var∗p(θ |X )[pWk,Xm+1(θ˜ )|X ].
Since we do not have the closed form solutions, we can estimate the posterior mean
and variance of Sh(Wk) and pWk,Xm+1 through the sampling approach. By applying
the Gibbs sampler in online Appendix E, we can generate posterior samples θ˜
(b) ∼
p(θ |X ) with b = 1,2, . . . ,B. At any θ˜ (b), we can compute Sh(Wk|θ˜
(b)
) following the
description in Section 3.3. The expected contribution from Wk to the variance of Xm+1
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is estimated by Ê
∗
[Sh(Wk)|X ] = S¯h(Wk|X ) = 1B ∑
B
b=1 Sh(Wk|θ˜
(b)
). And the overall
estimation uncertainty can be estimated by sample variance,
V̂ar
∗
[Sh(Wk)|X ] = 1B−1
B
∑
b=1
[
Sh(Wk|θ˜
(b)
)− S¯h(Wk|X )
]2
. (20)
Similarly, we can estimate the expected criticality by Ê
∗
[pWk,Xm+1 |X ] = p¯Wk,Xm+1 =
1
B
∑Bb=1 pWk,Xm+1(θ˜
(b)
) and estimate the overall estimation uncertainty by
V̂ar
∗
[pWk,Xm+1 |X ] =
1
B−1
B
∑
b=1
[
pWk,Xm+1(θ˜
(b)
)− p¯Wk,Xm+1
]2
. (21)
4.3. Sensitivity Study of Risk Analysis to Model Risk
In this section, we propose the BN-SV-MR based sensitivity analysis, and also
provide the UQ and SA procedure in Algorithm 1. It allows us to analyze the effect of
model risk on the production process risk analysis and criticality assessment for each
CPP/CQA. Steps (1)–(3) estimate Var∗[Sh(Wk)|X ] to quantify the overall impact of
model risk on Sh(Wk) estimation. Steps (4)–(14) further study its sensitivity to the
estimation uncertainty induced from each relevant SN parameter.
Here we use Var∗[Sh(Wk)|X ] for illustration and the similar idea can be applied to
CPPs/CQAs criticality assessment Var∗[pWk,Xm+1 |X ]. Let θ (Wk,Xm+1) ⊂ θ represent
the subset of BN parameters impacting Sh(Wk|θ ). We set θ (Wk,Xm+1) = {v2i : Xi ∈
N(Wk,Xm+1)}∪ {β 2i j : Xi,X j ∈ N(Wk,Xm+1),Xi ∈ Pa(X j)}, where N(Wk,Xm+1) is the
set containing nodes located along paths from Wk to Xm+1; see Section 3.3. Notice that
µ has no impact on Sh(Wk|θ ). Since SV can appropriately account for the probabilis-
tic dependence characterized by p(θ |X ) and structural interactions, we can measure
the contribution from any parameter θ` ∈ θ (Wk,Xm+1) through the posterior variance
decomposition,
Var∗[Sh(Wk)|X ] = ∑θ`∈θ (Wk,Xm+1)Sh∗θ`
[
Sh
(
Wk
∣∣∣θ˜ )∣∣∣X ]= ∑θ`∈θ (Wk,Xm+1)Sh∗θ` [Sh(Wk)|X ] .
The proposed BN-SV-MR sensitivity analysis can provide the comprehensive and in-
terpretable understanding on how the model risk or knowledge limitation over each
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related part of production process (i.e., represented by parameter θ` ∈ θ (Wk,Xm+1))
impacts on the system risk analysis.
Algorithm 1: Procedure for the BN-SV-MR Based UQ and SA
Input: BN structure G(N|θ ), dataX , number of samples Npi , B, BO and BI , index subset
Lk.
Output: Return Ŝh
∗
θ` [Sh(Wk)|X ] and Ŝh
∗
θ`
[
pWk ,Xm+1
∣∣X ] for any
Wk ∈W = {Xp∪Xa∪ e}.
(1) Call Algorithm 3 in Appendix E.1.3 to obtain the posterior samples
θ˜
(b)
= (µ˜ (b),v˜(b)2,β˜
(b)
) with b = 1,2, . . . ,B for UQ and θ˜
(bO)
= (µ˜ (bO),v˜(bO)2,β˜
(bO)
)
with bO = 1,2, . . . ,BO for SA;
(2) Call Algorithm 2 in Appendix D to compute Sh(Wk|θ˜
(b)
) and criticality
pWk ,Xm+1(θ˜
(b)
) for b = 1,2, . . . ,B;
(3) Calculate the overall estimation uncertainty by using V̂ar
∗
[Sh(Wk)|X ] and
V̂ar
∗
[pWk ,Xm+1 |X ] in Equations (20) and (21);
(4) Randomly generate Npi permutations, pin ∼Π(Lk) with n = 1, . . . ,Npi ;
for Each pin do
(5) Set ĉ(Ppin(1)(pin)) = 0;
for `= 1, . . . ,Lk do
if ` < Lk then
for bO = 1, . . . ,BO do
(7) Set initial value θ (bO,0)J = θ˜
(bO)
J withJ = Ppin(`+1)(pin);
for t = 1, . . . ,T do
(8) For each θJ (`) ∈ θJ , generate
θ (bO,t)J (`) ∼ p(θJ (`)|X ,θ˜
(bO)
Lk−J ,θ
(bO,t)
J (1) , . . . ,θ
(bO,t)
J (`−1),θ
(bO,t−1)
J (`+1) ,
. . . ,θ (bO,t−1)J (J) ) by applying Equations (17)/(18)/(19) for the case
with complete data or Equations (E.1)/(E.2)/(E.3) for cases with
mixing data (see the online Appendix). Obtain the new sample
θ (bO,t)J ;
(9) Set θ˜
(bO,bI)
J = θ
(bO,(bI−1)h+1)
J with some constant integer h to reduce
the correlation between consecutive samples;
(10) Compute ĉ(Ppin(`+1)(pin)) by Equations (25) and (27);
else
(11) Set ĉ(Ppin(`+1)(pin)) = V̂ar
∗
[Sh(Wk)|X ] and V̂ar
∗
[pWk ,Xm+1 |X ];
(12) Compute ∆pin(`)c(pin) = ĉ(Ppin(`+1)(pin))− ĉ(Ppin(`)(pin));
(13) Estimate Ŝh
∗
θ` [Sh(Wk)|X ] and Ŝh
∗
θ`
[
pWk ,Xm+1
∣∣X ] by using Equations (26) and
(28).
Then, we derive SV, Sh∗θ` [Sh(Wk)|X ] = ∑J⊂Lk/{`}
(Lk−|J |−1)!|J |!
Lk!
[c(J ∪{`})− c(J )], to measure the contribution from the estimation uncertainty
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of θ`. Denote the size of relevant BN parameters by Lk = |θ (Wk,Xm+1)| and de-
note the index set by Lk. Thus, θ (Wk,Xm+1) = θLk . We further denote any sub-
set by θJ ⊂ θ (Wk,Xm+1) with size J = |θJ | and the corresponding index set J =
{J (1),J (2), . . . ,J (J)} ⊂Lk. For anyJ ⊂Lk, the cost function is given as,
c(J ) = E∗p(θLk−J |X )
[Var∗p(θJ |θLk−J ,X )
[Sh(Wk)|θ˜Lk−J ]], (22)
where θLk−J = θLk\J . Denote a permutation ofLk as pi and define the set P` (pi) as
the index set preceding ` in pi . The SV can be rewritten as,
Sh∗θ` [Sh(Wk)|X ] = ∑
pi∈Π(Lk)
1
Lk!
[c(P` (pi)∪{`})− c(P` (pi))] , (23)
where Π(Lk) denotes the set of all Lk! permutations ofLk.
The number of all possible subsets J could grow exponentially as Lk increase.
To address this computational issue, we use the Monte Carlo sampling approach, Ap-
proShapley, suggested by Song et al. (2016) and Castro et al. (2009), by estimating the
Shapley value in (23) by
Ŝh
∗
θ` [Sh(Wk)|X ] =
1
Npi
Npi
∑
n=1
[c(P` (pin)∪{`})− c(P` (pin))], 1Npi
Npi
∑
n=1
∆`c(pin), (24)
where Npi denotes the number of permutations pi1, . . . ,piNpi randomly generated from
Π(Lk) and ∆`c(pin) = c(P` (pin)∪{`})−c(P` (pin)) is the incremental posterior variance
Var∗[Sh(Wk)|X ] induced by including the `-th BN parameter input in P` (pin).
To efficiently compute ∆`c(pin), according to Song et al. (2016), we compute c(·)
in an order of exact location in permutation pin. Assume the permutation index set
pin = {pin(1),pin(2), . . . ,pin(Lk)}, we compute c(Ppin(`)(pin)) as the order of pin(`) for `=
1, . . . ,L, where c(Ppin(1)(pin)) = c( /0) = 0, c(Ppin(Lk+1)(pin)) = c(pin) =Var
∗[Sh(Wk)|X ],
and Ppi( j+1) denotes Ppi( j)(pi)∪{pi( j)} for 0< j < Lk. Then we can compute the incre-
mental variance related to each θpin(`) for `= 1, . . . ,Lk: ∆pin(`)c(pin) = c(Ppin(`+1)(pin))−
c(Ppin(`)(pin)). Since {θpin(1),θpin(2) . . . ,θpin(Lk)}, θ pin is just a permutation of θLk , it is
equivalent as computing ∆`c(pin) for all θ` under permutation pin.
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We can not analytically compute c(J ) in (22) and a Monte Carlo sampling
approach is developed to estimate it. Since the posterior samples obtained from
the Gibbs sampler in online Appendix E.1.3 can not be directly used to estimate
E∗p(θLk−J |X )
[Var∗p(θJ |θLk−J ,X )
[Sh(Wk)|θ˜Lk−J ]], we introduce a nested Gibbs sam-
pling approach. The posterior sample θ˜
(bO)
Lk−J can be directly obtained by applying the
Gibbs sampling in Appendix E.1.3 to generate θ˜
(bO) ∼ p(θ |X ) and keeping compo-
nents with indexLk−J for bO = 1, . . . ,BO. They are called “outer” samples and we
use them to estimate E∗p(θLk−J |X )
. At each θ˜
(bO)
Lk−J , a conditional sampling is further
developed to generate samples from p(θJ |θ˜
(bO)
Lk−J ,X ). More specifically, we set the
initial value θ (bO,0)J = θ˜
(bO)
J . In each t-th MCMC iteration, given the previous sample
θ (bO,t−1)J , we apply the Gibbs sampling to sequentially generate one sample from the
conditional posterior for each θJ (`) ∈ θJ with `= 1, . . . , |J |,
θ (bO,t)J (`) ∼ p
(
θJ (`)
∣∣∣∣X ,θ˜ (bO)Lk−J ,θ (bO,t)J (1) , . . . ,θ (bO,t)J (`−1),θ (bO,t−1)J (`+1) , . . . ,θ (bO,t−1)J (|J |) ) .
By repeating this procedure, we can get samples θ (bO,t)J with t = 0, . . . ,T . We keep one
for every h samples to reduce the correlations between consecutive samples. Conse-
quently, we obtain “inner” samples θ˜
(bO,bI)
J with bI = 1, . . . ,BI .
Thus, this nested Gibbs sampling can generate BO ·BI samples {(θ˜
(bO,bI)
J ,θ˜
(bO)
Lk−J ) :
bO = 1, . . . ,BO and bI = 1, . . . ,BI}. For any J ⊂ Lk, the cost function can be esti-
mated as,
ĉ(J ) =
1
BO
BO
∑
bO=1
{
1
BI−1
BI
∑
bI=1
[
Sh(Wk|θ˜
(bO,bI)
J ,θ˜
(bO)
Lk−J )− S¯h(Wk|θ˜
(bO)
Lk−J )
]2}
,
(25)
where S¯h(Wk|θ˜
(bO)
Lk−J ) = ∑
BI
bI=1
Sh(Wk|θ˜
(bO,bI)
J ,θ˜
(bO)
Lk−J )/BI . By plugging ĉ(J ) into
Equation (24), we can quantify the contribution from the estimation uncertainty on
each BN parameter θ` ∈ θLk ,
Ŝh
∗
θ` [Sh(Wk)|X ] =
1
Npi
Npi
∑
n=1
∆`ĉ(pin), (26)
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where ∆`ĉ(pin) = ĉ(P` (pin) ∪ {`})− ĉ(P` (pin)) and it is equivalent with computing
∆pin(`)ĉ(pin) = ĉ(Ppin(`+1)(pin)) − ĉ(Ppin(`)(pin)) for all ` = 1, . . . ,Lk. Similarly, for
CPP/CQA criticality assessment, we can estimate the cost function,
ĉ′(J ) =
1
BO
BO
∑
bO=1
{
1
BI−1
BI
∑
bI=1
[
pWk,Xm+1(θ˜
(bO,bI)
J ,θ˜
(bO)
Lk−J )− p¯Wk,Xm+1(θ˜
(bO)
Lk−J )
]2}
,
(27)
where p¯Wk,Xm+1(θ˜
(bO)
Lk−J ) = ∑
BI
bI=1
pWk,Xm+1(θ˜
(bO,bI)
J ,θ˜
(bO)
Lk−J )/BI . Then, we estimate
the contribution from the estimation uncertainty of θ` on the criticality assessement,
Ŝh
∗
θ`
[
pWk,Xm+1
∣∣X ]= 1
Npi
Npi
∑
n=1
∆`ĉ′(pin). (28)
5. Empirical Study
To study the performance of the proposed framework, we consider the produc-
tion process example for a monoclonal antibody (mAbs) bio-drug. The production
procedure starts from main fermentation to API, including the main operation steps:
(1) main fermentation, (2) centrifugation, (3) chromatography/purification, and (4) fil-
tration. The simplified relational graph for this production procedure is provided in
Figure 4. Here, we only consider the dominant CPPs/CQAs in each step, and the im-
pacts of remaining factors are included in e. To provide a clear illustration, CPPs and
CQAs are grouped in Figure 4. In total, this BN has 21 nodes, consisting of 10 CPPs
(Xp) and 8 CQAs (Xa) for intermediate product and 3 CQAs (Y) for the final drug
substance. The size of parameters θ is 91, including 21 µi’s, 21 vi’s, and 49 βi j’s pa-
rameters. Even though there are many factors impacting on the bio-drug quality, the
amount of real-world batch data could be very limited. Thus, it is important to ex-
plore the causal relationships of the biopharmaceutical production process, which can
reduce the model risk and also increase the interpretability for process risk and sensi-
tivity analysis. Given very limited process batch data, the empirical results show that
we can provide reliable and interpretable risk analysis conclusions.
To study the performance of the proposed framework, we generate the simulated
production process data X , which mimics the “real-world data collection.” The BN
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Figure 4: Relational graph for an antibody bio-drug API production process.
with parameters θ c = (µ c,(v2)c,β c) characterizing the underlying risk and interde-
pendence is used for data generation, which is built on the biomanufacturing domain
knowledge; see the detailed setting in online Appendix F. To assess the performance
of the proposed framework, we assume that the true parameter values are unknown.
We empirically study the convergence of BN parameter inference in Appendix G.
5.1. Risk Analysis and Criticality Assessment of CPPs/CQAs
In the real applications, the amount of biopharmaceutical production batch data
could be limited. In the following empirical study, we generate the data X with
size R = 30 to study the performance of the proposed risk and sensitivity analy-
sis framework. For any CQA Xi of interest, at each posterior sample θ˜ , we fol-
low Algorithm 2 in Appendix D to assess the criticality of CPPs/CQAs and other
factors by applying Equation (14). Then, we can estimate the expected critical-
ity for any input Wk ∈ {Xp(N′)∪Xa(N′)∪ e(N′)}. Specifically, in the k-th macro-
replication, we first generate the “real-world” batch data X (k). Let pWk,Xi(θ˜ ) =
Shi(Wk|θ˜ )/Var(Xi|θ˜ ) denote the criticality of Wk to the variance of Xi. We esti-
mate the expected criticality E[pWk,Xi ] =
∫∫
pWk,Xi(θ )dP(θ |X )dP(X |θ c)× 100% by
using Ê[pWk,Xi ] =
1
KB ∑
K
k=1∑
B
b=1 pWk,Xi(θ˜
(k,b)
)× 100% with θ˜ (k,b) ∼ p(θ |X (k)) for
k = 1, . . . ,K and b = 1, . . . ,B, with K = 20 and B = 1000, and then record the results
in terms of percentage (%) in Tables 1 and 2.
The BN model risk is characterized by the posterior p(θ |X ) and its impact on the
CPPs/CQAs criticality assessment can be quantified by the posterior standard deviation
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Table 1: The estimated criticality level Ê[pWk ,Xi ] and standard deviation ŜD[pWk ,Xi ] (in %) of any input CPP
or other factor Wk impacting on the variance of intermediate or final product CQA Xi.
Ê[pWk,Xi ] Xi = X5 X6 X7 X10 X11 X14 X15 X16 X19 X20 X21
Wk = X1 8.91(3.09) 8.93(3.11) 9.42(3.59) 8.51(2.87) 8.51(2.87) 5.87(1.88) 5.87(1.88) 5.87(1.88) 5.52(1.74) 5.52(1.74) 5.52(1.74)
X2 0.82(0.38) 0.76(0.35) 0.96(0.75) 0.75(0.32) 0.75(0.32) 0.52(0.21) 0.52(0.21) 0.52(0.2) 0.49(0.19) 0.49(0.19) 0.49(0.19)
X3 4.28(1.6) 4.33(1.61) 4.22(1.97) 4.05(1.46) 4(1.44) 2.75(0.93) 2.75(0.93) 2.75(0.93) 2.59(0.86) 2.59(0.86) 2.59(0.86)
X4 85.75(4.02) 85.73(4.03) 83.29(4.84) 81.52(4.55) 81.6(4.53) 58.2(7.32) 58.22(7.32) 58.2(7.32) 55.09(7.21) 55.09(7.21) 55.06(7.21)
e5 0.23(0.1) 0.05(0.04) 0.04(0.04) 0.03(0.02) 0.03(0.02) 0.03(0.02) 0.03(0.02) 0.03(0.02) 0.03(0.02)
e6 0.24(0.1) 0.04(0.03) 0.05(0.04) 0.03(0.02) 0.03(0.02) 0.03(0.02) 0.03(0.02) 0.03(0.02) 0.03(0.02)
e7 2.11(0.86) 0.05(0.04) 0.06(0.04) 0.03(0.02) 0.03(0.02) 0.03(0.02) 0.03(0.02) 0.03(0.02) 0.03(0.02)
X8 1.02(0.41) 1.01(0.41) 0.68(0.24) 0.68(0.25) 0.69(0.25) 0.64(0.23) 0.64(0.23) 0.64(0.23)
X9 3.91(1.42) 3.86(1.41) 2.66(0.9) 2.68(0.91) 2.67(0.9) 2.51(0.84) 2.51(0.84) 2.51(0.84)
e10 0.1(0.04) 0.02(0.01) 0.02(0.01) 0.02(0.01) 0.02(0.01) 0.02(0.01) 0.02(0.01)
e11 0.12(0.05) 0.02(0.01) 0.02(0.02) 0.02(0.01) 0.02(0.01) 0.02(0.01) 0.02(0.01)
X12 1.86(0.63) 1.9(0.66) 1.86(0.63) 1.76(0.59) 1.76(0.59) 1.76(0.59)
X13 27.31(6.46) 27.18(6.45) 27.3(6.46) 25.72(6.09) 25.73(6.09) 25.71(6.09)
e14 0.02(0.01) <0.01(<0.01) <0.01(<0.01) <0.01(<0.01)
e15 0.06(0.02) <0.01(<0.01) <0.01(<0.01) <0.01(<0.01)
e16 0.02(0.01) <0.01(<0.01) <0.01(<0.01) <0.01(<0.01)
X17 1.27(0.45) 1.27(0.43) 1.27(0.43)
X18 4.23(1.39) 4.26(1.39) 4.3(1.41)
e19 0.04(0.01)
e20 0.01(<0.01)
e21 0.01(<0.01)
Table 2: The estimated criticality level Ê[pWk ,Xi ] and standard deviation ŜD[pWk ,Xi ] (in %) of any input CQA
Wk on the variance of intermediate or final product CQA Xi.
Ê[pWk,Xi ] Xi = X10 X11 X14 X15 X16 X19 X20 X21
Wk = X5 43.1(11.18) 38.05(11.44) 28.68(6.48) 28.46(6.68) 28.44(6.48) 27.05(6.14) 26.99(6.11) 27.01(6.07)
X6 37.97(10.79) 42.44(11.27) 28.64(6.32) 28.8(6.5) 28.88(6.28) 27.13(5.98) 27.18(5.95) 27.14(5.91)
X7 13.91(4.42) 14.52(4.92) 10.11(2.62) 10.2(2.73) 10.11(2.67) 9.59(2.49) 9.6(2.49) 9.59(2.48)
X10 37.17(6.55) 33.62(9.62) 34.59(6.7) 33.52(5.69) 33.01(5.16) 33.3(5.02)
X11 33.64(6.42) 37.24(9.74) 36.23(6.72) 33.44(5.69) 33.95(5.2) 33.63(5.03)
X14 32.65(12.69) 31.91(7.8) 33.74(6.69)
X15 21.49(12.22) 25.1(6.9) 25.25(5.52)
X16 40.31(14.51) 37.45(7.64) 35.42(7.85)
(SD), SD∗[pWk,Xi(θ˜ )|X ] . Based on the results from K macro-replications, we compute
the expected SD for criticality estimation, SD[pWk,Xi ] =
√
E[Var∗(pWk,Xi(θ˜ )|X )]×
100%, with the estimate,
ŜD[pWk,Xi ] =
√√√√ 1
K(B−1)
K
∑
k=1
B
∑
b=1
[
pWk,Xi
(
θ˜
(k,b)
)
− p¯(k)Wk,Xi
]2
×100%
where p¯(k)Wk,Xi =
1
B ∑
B
b=1 pWk,Xi(θ˜
(k,b)
). In Tables 1 and 2, we record the results of SD in
terms of percentage (%) in the bracket.
For the example shown in Figure 4, the CQAs of intermediate products include
nodes {X5,X6,X7,X10,X11,X14,X15,X16} and the final API CQAs are represented by
nodes {X19,X20,X21}. For each CQA output Xi, we record the criticality with the
estimated mean Ê[pWk,Xi ] and SD ŜD[pWk,Xi ] from any CPP or other factor Wk ∈
{Xp(N′)∪ e(N′))} in Table 1. Then, we record the criticality of CQAs Wk to each
following CQA Xi in Table 2. Under the example setting, we can see that the variations
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in X4 (oxygen in main fermentation) and X13 (temperature in chromatography) have the
dominant impact on both intermediate and final product CQAs’ variance. Compared
with main fermentation and chromatography, the other two operation units (i.e., cen-
trifuge and filtration) have relatively small impact on the final product quality variation.
The CQAs after main fermentation, i.e., {X5,X6,X7}, together account for
about 50% of final product CQA variance; and CQAs after chromatography, i.e.,
{X14,X15,X16} together account for about 90% of final CQA variation. Thus, the CQAs
of intermediate product close to the end of production process provides better explana-
tion of the CQAs variation of final API and we can predict more accurate on the API
quality. This information can be used to guide the production process quality control.
In addition, according to Table 2, compared with bioburden X7, the CQAs impurities
and protein X5 and X6 contribute relatively higher to the following intermediate product
and final product CQAs variation.
5.2. Uncertainty Quantification and Sensitivity Analysis
Here we consider the product protein content X20 in Figure 4 to illustrate the perfor-
mance of the proposed sensitivity analysis. Based on the results in Table 1, the CPPs
X4 and X13 have the dominant contributions to the variance of output X20 and they
also have the relatively high estimation uncertainty. Thus, we conduct the BN-SV-MR
sensitivity analysis to get the comprehensive information on how the BN model risk
impacts on the criticality assessment for pX4,X20 and pX13,X20 .
Given the data X , we have the posterior variance decomposition studying the
criticality estimation error induced by the model risk, Var∗p(θ |X )[pWk,Xi(θ˜ )|X ] =
∑θ`∈θ (Wk,Xi)Sh
∗
θ`
[
pWk,Xi(θ˜ )
∣∣∣X ] . Then, we can estimate the relative contribution from
each BN parameter θ` ∈ θ (Wk,Xi) with EPθ`(pWk,Xi) ≡ E
[
Sh∗θ`
[
pWk ,Xi (θ˜ )
∣∣∣X ]
Var∗p(θ |X )
[
pWk ,Xi (θ˜ )
∣∣∣X ]
]
.
In the k-th macro-replication, given the data X (k), we can estimate the contribu-
tion from each θ` by using Ŝh
∗
θ`
[
pWk,Xi(θ˜ )
∣∣∣X (k)] and V̂ar∗p(θ |X ) [ pWk,Xi(θ˜ )∣∣∣X (k)]
which is estimated by using Npi = 500, BO = 5 and BI = 20; see Song et al. (2016)
for the selection of sampling parameter setting. Thus, we have ÊPθ`(pWk,Xi) ≡
1
K ∑
K
k=1
Ŝh
∗
θ`
[
pWk ,Xi (θ˜ )
∣∣∣X (k)]
V̂ar
∗
p(θ |X )
[
pWk ,Xi (θ˜ )
∣∣∣X (k)] with K = 20.
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The parameters contributing to the estimation of Sh20(X4) include v24 and 18 linear
coefficients β on the paths from node X4 to node X20. The parameters contributing
to the estimation of Sh20(X13) include v213 and 6 linear coefficients β located on the
paths from X13 to X20. Due to the space limit, we only present the top five parame-
ters contributing most to the estimation uncertainty of criticality pX4,X20 and pX13,X20 ,
and aggregate the results for remaining parameters. The sensitivity analysis results,
ÊPθ`(pWk,Xi)±SE
[
ÊPθ`(pWk,Xi)
]
, for pX4,X20 and pX13,X20 are shown in Table 3, where
SE stands for the standard error (SE). Notice that the parameters that contribute the
most to the estimation error of the criticality pX4,X20 and pX13,X20 are the variance pa-
rameters of CPPs (v24 and v
2
13). The estimation errors of linear coefficients have similar
and relatively small contributions. This information can guide the production process
monitoring and data collection to efficiently reduce the estimation uncertainty of criti-
cality assessment and improve our knowledge on the underlying probabilistic interde-
pendence of the biopharmaceutical production process.
Table 3: The estimated relative contribution of each BN parameter estimation uncertainty (in terms of %) on
criticality assessment ÊPθ` (pWk ,Xi )±SE
[
ÊPθ` (pWk ,Xi )
]
for pX4 ,X20 and pX13,X20 .
θ` ∈ θ (X4,X20) v24 β11,15 β10,14 β15,20 β14,20 rest
ÊPθ`(pX4,X20) 73.75±1.96 1.59±0.13 1.58±0.19 1.57±0.21 1.56±0.13 19.95±4.70
θ` ∈ θ (X13,X20) v213 β13,15 β16,20 β15,20 β13,16 rest
ÊPθ`(pX13,X20) 68.16±6.40 5.57±0.50 5.54±0.49 5.42±0.44 5.23±0.46 10.08±8.87
6. Conclusions
Driven by the critical challenges in biomanufacturing, we propose a new BN based
risk and sensitivity analysis framework to facilitate the production process learning
and stability control. Since hundreds of factors could impact on the product quality
and the amount of real-world batch data is often very limited, we explore the causal
relationships and develop a BN characterizing the production process probabilistic in-
terdependence. Considering SV can correctly account for probabilistic dependence
and structural interactions, we propose the BN-SV based risk analysis to assess the
criticality of each random input on the variance of product quality attributes. Given
limited real-world batch data, there exists the model risk. We further introduce the
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BN-SV-MR based UQ and SA that can provide the comprehensive understanding of
how the model risk impacts on the end-to-end production process risk analysis and
CPPs/CQAs criticality assessment. An antibody bio-drug production case is used to
study the performance of the proposed framework.
There are several directions worth further investigation. In this paper, we ignore
the risk induced by the model family selection error. How to quantify and incorporate
this source of uncertainty will be considered in the future research. In addition, built
on this study, we could develop new methodologies that can facilitate the production
process forward prediction and backward problem detection.
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Appendix A. Detailed Derivation of Equation (6)
In order to show Equation (6), we consider more general results as following,
Xn = µn+
mp
∑
k=1
γk,n(Xk−µk)+
n
∑
k=mp+1
γk,nek, (A.1)
for n=mp+1, . . . ,m+1, where γk,n is given as Equations (7) and (8). Notice according
to linear Gaussian model (4), we can write Xmp+1 = µmp+1+∑m
p
k=1βk,mp+1(Xk−µk)+
emp+1, where βk,mp+1 = 0 for k /∈ Pa(Xmp+1). Suppose Equation (A.1) holds for all
n = mp+1, . . . ,n0. For n = n0+1, by applying linear Gaussian model, we have
Xn0+1 = µn0+1+
n0
∑
k=1
βk,n0+1(Xk−µk)+ en0+1,
= µn0+1+
mp
∑
k=1
βk,n0+1(Xk−µk)+
n0
∑
`=mp+1
β`,n0+1
[
mp
∑
k=1
γk,`(Xk−µk)+
`
∑
k=mp+1
γk,`ek
]
+ en0+1, (A.2)
= µn0+1+
mp
∑
k=1
[
βk,n0+1+
n0
∑
`=mp+1
γk,`β`,n0+1
]
(Xk−µk)+
n0
∑
k=mp+1
[
n0
∑`
=k
γk,`β`,n0+1
]
ek
+ en0+1,
= µn0+1+
mp
∑
k=1
γk,n0+1(Xk−µk)+
n0+1
∑
k=mp+1
γk,n0+1ek. (A.3)
Step (A.2) follows by applying (A.1). Step (A.3) follows by applying Equations (7)
and (8). By mathematical induction, we can conclude that Equation (A.1) holds for all
n = mp+1, . . . ,m+1.
Appendix B. Detailed Derivation of Equation (12)
According to the linear representation (10), for any Xk1 ,Xk2 ∈ Xa(N′), the covari-
ance,
Cov(Xk1 ,Xk2) = Cov
 ∑
X`∈Xp(Xk1 )
γ`k1X`+
k1
∑
`=mp+1
γ`k1e`, ∑
X`∈Xp(Xk2 )
γ`k2X`+
k2
∑
`=mp+1
γ`k1e`

31
= ∑
X`∈{Xp(Xk1 )∩Xp(Xk2 )}
γ`k1γ`k2Var[X`]+
min(k1,k2)
∑
`=mp+1
γ`k1γ`k2Var[e`]
= ∑
X`∈{Xp(Xk1 )∩Xp(Xk2 )}
γ`k1γ`k2v
2
` +
min(k1,k2)
∑
`=mp+1
γ`k1γ`k2v
2
` ,
since CPPs X` ∈ Xp and error terms e` are mutually independent with each other.
Appendix C. Detailed Derivation of Equation (13)
We consider Wk andJ ⊂K ′/{k}. ForJ = /0, we have
(n′−|J |−1)!|J |!
n′!
[c(J ∪{k})− c(J )] = 1
n′
γ2kiVar(Wk).
For |J |= m′ with m′ = 1, . . . ,n′−1, we have
∑
{J :|J |=m′}
(n′−|J |−1)!|J |!
n′!
[c(J ∪{k})− c(J )]
= ∑
{J :|J |=m′}
(n′−m′−1)!m′!
n′!
[
γ2kiVar(Wk)+2 ∑
`∈J
γkiγ`iCov(Wk,W`)
]
=
(n′−m′−1)!m′!
n′!
{(
n′−1
m′
)
γ2kiVar(Wk) (C.1)
+2 ∑
`∈K ′/{k}
 ∑
{J :|J |=m′ and `∈J}
γkiγ`iCov(Wk,W`)
} (C.2)
=
1
n′
γ2kiVar(Wk)+2
(n′−m′−1)!m′!
n′!
(
n′−2
m′−1
)
∑
`∈K ′/{k}
γkiγ`iCov(Wk,W`) (C.3)
=
1
n′
γ2kiVar(Wk)+
2m′
n′(n′−1) ∑
`∈K ′/{k}
γkiγ`iCov(Wk,W`).
Step (C.1) holds because the number of all subsets J with size m′ is
(n′−1
m′
)
. In
Step (C.2), we shift the order of sums over J and `. Then, Step (C.3) holds be-
cause given W`, the number of subset {J : |J |= m′ and ` ∈J } is
(n′−2
m′−1
)
. So, we
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get the Shapley value,
Shi(Wk|θ ) = ∑
J⊂K /{k}
(n′−|J |−1)!|J |!
n′!
[c(J ∪{k})− c(J )]
=
n′−1
∑
m′=0
[
1
n′
γ2kiVar(Wk)+
2m′
n′(n′−1) ∑
`∈K ′/{k}
γkiγ`iCov(Wk,W`)
]
= γ2kiVar(Wk)+ ∑
`∈K ′/{k}
γkiγ`iCov(Wk,W`),
=

γ2kiv
2
k , Wk = Xk ∈ Xp(N′) or Wk = ek ∈ e(N′)
γ2kiVar(Xk|θ )+∑X`∈Xa(N′)/{Xk}
(
∑Xh∈{Xp(Xk)∩Xp(X`)} γhkγkiγh`γ`iv
2
h
+∑min(k,`)h=mp+1 γhkγkiγh`γ`iv
2
h
)
, Wk = Xk ∈ Xa(N′).
The last step is obtained by applying Equation (12).
Appendix D. Procedure for Production Process Risk Analysis
Given the BN parameters θ , we summarize the procedure for production process
BN-SV based risk analysis in Algorithm 2. Suppose that we consider several consecu-
tive operation steps corresponding to the (sub)graph G(N′|θ (N′)) with N′ ⊆N, and we
are interested in a single response Xi with mp < i≤ m+1. Our objective is to quantify
the contribution of each random input in G(N′|θ (N′)) to Var(Xi|θ ). For the complete
production process, we have N′ = N and Xi = Xm+1.
Algorithm 2: Procedure for Production Process BN-SV Based Risk Analysis
Input: BN parameters θ , subgraph G(N′|θ (N′)), response node Xi.
Output: Variance decomposition of Xi in terms of all random inputs within G(N′|θ (N′)).
(1) Identify node sets Xa(N′), Xp(N′) and e(N′) representing the random inputs in the
subgraph G(N′|θ (N′)); see Section 3.3.2;
(2) Calculate the Shapley value Shi(Wk|θ ) with Wk = Xk or ek by using Equation (13),
which measures the contribution from Wk to the variance of response CQA Xi;
(3) Provide the variance decomposition of Var(Xi|θ ) by using Equation (14), and obtain
the criticality of Wk on the variance of Xi: pWk ,Xi(θ ) = Shi(Wk|θ )/Var(Xi|θ ).
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Appendix E. Derivation and Procedure for BN Learning and Gibbs Sampler
Appendix E.1. Bayesian Learning for BN Model Risk Quantification
We derive the posterior distribution of BN model parameters p(θ |X ) and intro-
duce a Gibbs sampling approach to generate the posterior samples, θ˜
(b) ∼ p(θ |X )
with b = 1,2, . . . ,B quantifying the model risk. In Section Appendix E.1.1, we first
provide the derivation for conditional posterior distribution with complete production
process data described in Section 4.1. Considering the situations where we could have
some additional incomplete batch data (e.g., batches in the middle of production or
thrown away at certain production step based on the quality control strategy), we fur-
ther extend the Bayesian learning approach to cases with mixing data in Section Ap-
pendix E.1.2. Then, we provide the Gibbs sampling procedure to generate the posterior
samples θ˜
(b)
with b = 1,2, . . . ,B in Section Appendix E.1.3.
Appendix E.1.1. Knowledge Learning for Cases with Complete Production Process
Data
Following Section 4.1, we first derive the conditional posterior distribution for the
weight coefficient βi j,
p(βi j|X ,µ ,v2,β−i j) ∝
[
R
∏
r=1
p(x(r)j |x(r)Pa(X j))
]
p(βi j),
∝ exp
− R∑r=1 12v2j
[
(x(r)j −µ j)−βi j(x(r)i −µi)− ∑
k∈Pa( j)/{i}
βk j(x
(r)
k −µk)
]2
− 1
2τ(0)2i j
(
βi j−θ (0)i j
)2 ,
∝ exp
− 12v2j
R
∑
r=1
(
α(r)i βi j−m(r)i j
)2− 1
2τ(0)2i j
(
βi j−θ (0)i j
)2 ,
∝ exp
−β 2i j2
 R∑
r=1
α(r)2i
v2j
+
1
τ(0)2i j
+βi j
 R∑
r=1
α(r)i m
(r)
i j
v2j
+
θ (0)i j
τ(0)2i j
=N (θ (R)i j ,τ(R)2i j ),
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where θ (R)i j =
τ(0)2i j ∑
R
r=1α
(r)
i m
(r)
i j + v
2
jθ
(0)
i j
τ(0)2i j ∑
R
r=1α
(r)2
i + v
2
j
and τ(R)2i j =
τ(0)2i j v
2
j
τ(0)2i j ∑
R
r=1α
(r)2
i + v
2
j
with α(r)i =
x(r)i −µi, and m(r)i j = (x(r)j −µ j)−∑Xk∈Pa(X j)/{Xi}βk j(x
(r)
k −µk).
Second, we derive the conditional posterior distribution for the variance parameter
v2i = Var[Xi|Pa(Xi)] with i = 1,2, . . . ,m+1,
p(v2i |X ,µ ,v2−i,β ) ∝
[
R
∏
r=1
p(x(r)i |x(r)Pa(Xi))
]
p(v2i )
∝ (v2i )
−R/2−κ(0)i /2−1 exp
− 12v2j
R
∑
r=1
[
(x(r)i −µi)− ∑
Xk∈Pa(Xi)
βki(x
(r)
k −µk)
]2
∝ (v2i )
−R/2−κ(0)i /2−1 exp
{
− 1
2v2j
R
∑
r=1
u(r)2i −
λ (0)i
2v2j
}
= Inv-Γ
(
κ(R)i
2
,
λ (R)i
2
)
,
where κ(R)i = κ
(0)
i +R, λ
(R)
i = λ
(0)
i +∑
R
r=1 u
(r)2
i and u
(r)
i =(x
(r)
i −µi)−∑Xk∈Pa(Xi)βki(x
(r)
k −
µk).
Third, we derive the conditional posterior distribution of mean parameter µi with
i = 1,2, . . . ,m+1 for any CPP and CQA,
p(µi|X ,µ−i,v2,β ) ∝ p(µi)
R
∏
r=1
[
p(x(r)i |x(r)Pa(Xi)) ∏
j∈S (Xi)
p(x(r)j |x(r)Pa(X j))
]
∝ exp
{
− 1
2v2i
R
∑
r=1
[
(x(r)i −µi)− ∑
Xk∈Pa(Xi)
βki(x
(r)
k −µk)
]2
−
R
∑
r=1
∑
X j∈S (Xi)
1
2v2j
(x(r)j −µ j)− ∑
Xk∈Pa(X j)
βk j(x
(r)
k −µk)
2− 1
2σ (0)2i
(
µi−µ(0)i
)2}
,
∝ exp
− 12v2i
R
∑
r=1
(
µi−a(r)i
)2− R∑
r=1
∑
X j∈S (Xi)
− 1
2v2j
(
βi jµi− c(r)i j
)2
− 1
2σ (0)2i
(
µi−µ(0)i
)2}
,
∝ exp
−µ2i2
 R
v2i
+ ∑
X j∈S(Xi)
Rβ 2i j
v2j
+
1
σ (0)2i
+µi
 R∑
r=1
a(r)i
v2i
+
R
∑
r=1
∑
X j∈S (Xi)
βi jc
(r)
i j
v2j
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+
µ(0)i
σ (0)2i
)}
=N (µ(R)i ,σ
(R)2
i ),
where µ(R)i =σ
(R)2
i
 µ(0)i
σ (0)2i
+∑Rr=1
a(r)i
v2i
+∑Rr=1∑X j∈S(Xi)
βi jc
(r)
i j
v2j
 and 1
σ (R)2i
=
1
σ (0)2i
+
R
v2i
+∑X j∈S(Xi)
Rβ 2i j
v2j
, with a(r)i = x
(r)
i −∑Xk∈Pa(Xi)βk j(x
(r)
k − µk) and c(r)i j = βi jx(r)i −
(x(r)j −µ j)+∑Xk∈Pa(X j)/{Xi}βk j(x
(r)
k −µk).
Appendix E.1.2. Knowledge Learning for Cases with Mixing Data
Except the case with complete production data discussed in Section Appendix
E.1.1, we consider the cases with additional incomplete data corresponding to cer-
tain “Top Sub-Graph”, denoted by G(N′|θ (N′)) with N′ ⊆N, such that any CQA node
X j ∈ N′ has Pa(X j) ⊂ N′. Since batch data collected from biopharmaceutical produc-
tion process are usually limited, we want to fully utilize both complete and incomplete
data to estimate the BN model parameters and improve our knowledge of production
process.
Without loss of generality, we consider the real-world data including two data
sets X = {X1,X2} with the complete data X1 = {(x(r1)1 ,x(r1)2 , . . . ,x(r1)m+1) for r1 =
1,2, . . . ,R1} and the incomplete data X2 = {(x(r2)i : Xi ∈ N′) for r2 = R1 + 1,R1 +
2, . . . ,R}, where R = R1+R2. Our approach can be easily extended to cases with mul-
tiple incomplete data sets. We use the same prior distribution p(µ ,v2,β ) as shown in
Equation (15). Given the mixing data X = {X1,X2}, we can derive the posterior
distribution of θ ,
p(µ ,v2,β |X ) ∝
R1
∏
r1=1
[
m+1
∏
i=1
p(x(r1)i |x(r1)Pa(Xi))
]
R
∏
r2=R1+1
[
∏
Xi∈N′
p(x(r2)i |x(r2)Pa(Xi))
]
p(µ ,v2,β ).
For βi j with X j /∈N′ or v2i and µi with node Xi /∈N′, the conditional posterior is the same
as complete data case and we can utilize Equations (17), (18) and (19) by replacingX
withX1.
Thus, to derive the full Gibbs sampler, we only need to provide the updated condi-
tional posterior accounting for those nodes included in the incomplete data setX2. We
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first derive the conditional posterior distribution for weight parameter βi j with X j ∈N′.
p(βi j|X ,µ ,v2,β−i j) ∝
[
R1+R2
∏
r=1
p(x(r)j |x(r)Pa(X j))
]
p(βi j),
∝ exp
−R1+R2∑r=1 12v2j
[
(x(r)j −µ j)−βi j(x(r)i −µi)− ∑
k∈Pa( j)/{i}
βk j(x
(r)
k −µk)
]2
− 1
2τ(0)2i j
(
βi j−θ (0)i j
)2 ,
∝ exp
− 12v2j
R1+R2
∑
r=1
(
α(r)i βi j−m(r)i j
)2− 1
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with α(r)i = x
(r)
i − µi and m(r)i j = (x(r)j − µ j)−∑Xk∈Pa(X j)/{Xi}βk j(x
(r)
k − µk) for r =
1,2, . . . ,R.
Then, we derive the conditional posterior distribution for v2i with Xi ∈ N′,
p(v2i |X ,µ ,v2−i,β ) ∝
[
R1+R2
∏
r=1
p(x(r)i |x(r)Pa(Xi))
]
p(v2i ),
∝ (v2i )
−(R1+R2)/2−κ(0)i /2−1 exp
− 12v2j
R1+R2
∑
r=1
[
(x(r)i −µi)− ∑
Xk∈Pa(Xi)
βki(x
(r)
k −µk)
]2 ,
∝ (v2i )
−(R1+R2)/2−κ(0)i /2−1 exp
{
− 1
2v2j
R1+R2
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r=1
u(r)2i −
λ (0)i
2v2j
}
= Inv-Γ
(
κ(R1+R2)i
2
,
λ (R1+R2)i
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)
, (E.2)
where κ(R1+R2)i = κ
(0)
i +R and λ
(R1+R2)
i = λ
(0)
i +∑
R
r=1 u
(r)2
i with u
(r)
i = (x
(r)
i − µi)−
∑Xk∈Pa(Xi)βki(x
(r)
k −µk) for r = 1,2, . . . ,R.
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After that, we derive the conditional posterior for mean parameter µi with Xi ∈ N′,
p(µi|X ,µ−i,v2,β ) ∝ p(µi)
R1+R2
∏
r=1
p(x(r)i |x(r)Pa(Xi))
R1
∏
r1=1
∏
X j∈S (Xi)
p(x(r1)j |x(r1)Pa(X j))
·
R1+R2
∏
r2=R1+1
∏
X j∈S(Xi)∩N′
p(x(r2)j |x(r2)Pa(X j)),
∝ exp
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,
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µ(R1+R2)i = σ
(R1+R2)2
i
 µ(0)i
σ (0)2i
+∑R1+R2r=1
a(r)i
v2i
+∑R1r1=1∑X j∈S (Xi)
βi jc
(r1)
i j
v2j
+
∑Rr2=R1+1∑X j∈S (Xi)∩N′
βi jc
(r2)
i j
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=
1
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+
R1+R2
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+
∑X j∈S (Xi)
R1β 2i j
v2j
+ ∑X j∈S (Xi)∩N′
R2β 2i j
v2j
with a(r)i = x
(r)
i − ∑Xk∈Pa(Xi)βk j(x
(r)
k − µk)
and c(r)i j = βi jx
(r)
i − (x(r)j −µ j)+∑Xk∈Pa(X j)/{Xi}βk j(x
(r)
k −µk) for r = 1,2, . . . ,R. Here
for illustration, we have only provided the conditional posteriors with two datasets
X1 and X2. These derivations can be easily extended to similar cases with multiple
datasets collected from complete graph and different top sub-graphs.
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Appendix E.1.3. Gibbs Sampling Procedure for BN Model Bayesian Inference
Based on the derived conditional posterior distributions in Sections Appendix E.1.1
and Appendix E.1.2, we provide the Gibbs sampling procedure in Algorithm 3 to gen-
erate posterior samples θ˜
(b) ∼ p(θ |X ) with θ˜ (b) = (µ˜ (b),v˜(b)2,β˜ (b)) and b = 1, . . . ,B.
We first set the non-informative prior p(θ ) = p(µ ,v2,β ) as Equation (15), and generate
the initial point θ (0)= (µ (0),v(0)2,β (0)) by sampling from the prior. Within each t-th it-
eration of Gibbs sampling, given the previous sample θ (t−1) = (µ (t−1),v(t−1)2,β (t−1)),
we sequentially compute and generate one sample from the conditional posterior dis-
tribution for each parameter βi j, v2i and µi. By repeating this procedure, we can get
samples θ (t) = (µ (t),v(t)2,β (t)) with t = 1, . . . ,T . To reduce the initial bias and corre-
lations between consecutive samples, we remove the first T0 samples and keep one for
every h samples. Consequently, we obtain the posterior samples θ˜
(b) ∼ p(θ |X ) with
b = 1, . . . ,B.
Algorithm 3: Gibbs Sampling Procedure for BN Model Risk Quantification
Input: the prior p(θ ) and real-world dataX .
Output: Posterior samples θ˜
(b)
= (µ˜ (b),v˜(b)2,β˜
(b)
)∼ p(θ |X ) with b = 1, . . . ,B.
(1) Set the initial value θ (0) = (µ (0),v(0)2,β (0)) by sampling from prior p(θ );
for t = 1,2, . . . ,T do
(2) Given the previous sample θ (t−1) = (µ (t−1),v(t−1)2,β (t−1));
(3) For each βi j , generate β
(t)
i j ∼ p(βi j|X ,β (t)12 , . . . ,
β (t)i, j−1,β
(t−1)
i, j+1 , . . . ,β
(t−1)
m,m+1,µ
(t−1),v(t−1)2) through Equation (17) for complete data
or (E.1) for mixing data;
(4) For each v2i , generate v
(t)2
i ∼ p(v2i |X ,β (t),v(t)21 ,
. . . ,v(t)2i−1 ,v
(t−1)2
i+1 , . . . ,v
(t−1)2
m+1 ,µ
(t−1))) through Equation (18) for complete data or
(E.2) for mixing data;
(5) For each µi, generate µ
(t)
i ∼ p(µi|X ,β (t),v(t),2,
µ(t)1 , . . . ,µ
(t)
i−1,µ
(t−1)
i+1 , . . . ,µ
(t−1)
n ) through Equation (19) for complete data or (E.3)
for mixing data;
(6) Obtain a new posterior sample θ (t) = (µ (t),v(t)2,β (t));
(7) Set θ˜
(b)
= θ (T0+(b−1)h+1) with some constant integer T0 and h, to reduce the initial
bias and correlation between consecutive samples.
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Appendix F. Simulated Biopharmaceutical Production Data
To study the performance of proposed framework, we generate the simulated pro-
duction process dataX , which mimics the “real-world data collection.” The BN with
parameters θ c characterizing the underlying production process interdependence is
used for data generation, which is built according to the biomanufacturing domain
knowledge. The ranges of CPPs/CQAs are listed Table F.4. For each CPP X j ∈ Xp
with range [xlowj ,x
up
j ], we can specify the marginal distribution X j ∼N (µcj ,(vcj)2) with
mean µcj = (xlowj + x
up
j )/2 and standard deviation v
c
j = (x
up
j − xlowj )/4. For each CQA
Xi ∈ {Xa∪Y} with range [xlowi ,xupi ], we have mean µci = (xlowi + xupi )/2 and marginal
variance Var(Xi) = [(x
up
i − xlowi )/4]2. Based on Equation (14), the corresponding pa-
rameter vci can be computed through back-engineering. For the complex interdepen-
dence, Table F.5 provides the relative associations with levels (i.e., high, median, low)
between input CPPs/CQAs with output CQAs in each operation unit, which is built
based on the “cause-and-effect matrix” in Mitchell (2013). For the high, median and
low association between Xi to X j, we set the coefficient β ci j = 0.9,0.6,0.3 respectively.
Thus, we can specify the underlying true parameters θ c = (µ c,(v2)c,β c). To mimic the
“real-world” data collection, we generate the production batch data X using the BN
model with θ c. Then, to assess the performance of proposed framework, we assume
that the true parameter values are unknown.
Table F.4: Range of CPPs/CQAs in the production procedure.
Process Unit Operation CPP Range CQA Range
Main Fermentation pH 6.8-7.2 impurities 3-11 pl
temperature 20-30 C protein content 1-5 g/L
Oxygen 2.5-7.5% bioburden 5-15 CFU/100mL
agitation rate 1.1-2.5 m/s
Centrifuge temperature 20 to 30 C impurities 3-11 pl
rotation speed 3-5K RPM protein content 5-15 CFU/100mL
Chromatography pooling window 10-30 min impurities 3-11 pl
temperature 2-10 C protein content 1-5 g/L
bioburden 5-15 CFU/100mL
Filtration size of sieve 0.1-0.5 um impurities 3-11 pl
flow rate 25-100 mL/min protein content 1-5 g/L
bioburden 5-15 CFU/100mL
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Table F.5: Relative association between input CPPs/CQAs with output CQAs in each process unit operation.
Process Unit Operation Input CPPs/CQAs Output CQAs
impurities protein content bioburden
Main Fermentation pH high high low
temperature high high low
Oxygen high high low
agitation rate high high low
Centrifuge temperature medium medium —
rotation speed medium medium —
impurities (main fermentation) medium medium —
protein content (main fermentation) medium medium —
bioburden (main fermentation) medium medium —
Chromatography pooling window high medium high
temperature high medium high
impurities (centrifuge) high medium high
protein content (centrifuge) high medium high
Filtration size of sieve low medium medium
flow rate low medium medium
impurities (chromatography) low medium medium
protein content (chromatography) low medium medium
bioburden (chromatography) low medium medium
Appendix G. Study the Bayesian Learning and Inference
To study the performance of proposed framework, we generate the simulated pro-
duction process dataX , which mimics the “real-world data collection.” The BN with
parameters θ c = (µ c,(v2)c,β c) characterizing the underlying risk and interdependence
is used for data generation, which is built on the biomanufacturing domain knowledge;
see the detailed setting in online Appendix Appendix F.
To assess the performance of proposed framework, we assume that the true pa-
rameter values are unknown. We empirically study the convergence of BN pa-
rameter inference. In each k-th macro-replication, we first mimic the “real-world”
production batch data collection through generating X (k) = {X(k)1 , . . . ,X(k)R } with
X(k)i ∼ F(X|θ c) for i = 1, . . . ,R and k = 1, . . . ,K. Then, we generate B posterior
samples θ˜
(k,b) ∼ p(θ |X (k)) with b = 1,2, . . . ,B. For the Gibbs sampler in Algo-
rithm 3 provided in online Appendix Appendix E.1.3, we set the initial warm-
up length T0 = 500 and step-size h = 10. With different size of complete “real-
world” batch data R = 30,100,500, we compute the mean squared error (MSE)
for each parameter θ` ∈ θ : MSE(θ`) =
∫∫ (
θ`−θ c`
)2 dP(θ`|X )dP(X |θ c). Based
on K = 20 macro-replications and B = 1000 posterior samples of BN parameters,
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we estimate MSE(θ`) with M̂SE(θ`) =
1
KB
∑Kk=1∑
B
b=1
(
θ˜ (k,b)` −θ c`
)2
. Since the to-
tal number of parameters is large, we further group parameters by mean µ , condi-
tional variance v2 and linear coefficients β , and take average of the sample MSE
respectively: M̂SE(µ ) = 1|µ | ∑θ`∈µ M̂SE(θ`), M̂SE(v
2) = 1|v2| ∑θ`∈v2 M̂SE(θ`), and
M̂SE(β ) = 1|β | ∑θ`∈β M̂SE(θ`). The corresponding results are reported in Table G.6.
As the size of real-world data R increases, the average MSE decreases, which implies
the posterior samples obtained by Gibbs sampling procedure can converge to the true
parameters.
Table G.6: The MSE of µ , v2 and β esimated by using the Gibbs sampling.
Batch Data Size M̂SE(µ ) M̂SE(v2) M̂SE(β )
R = 30 0.122±0.032 0.276±0.029 0.0225±0.0013
R = 100 0.075±0.023 0.061±0.006 0.0063±0.0004
R = 500 0.009±0.003 0.013±0.001 0.0011±0.00004
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